Advancements in Nano-Drug Delivery Systems for Effective Management of Periodontitis: A Comprehensive Review
DOI:
https://doi.org/10.55006/biolsciences.2024.4407Keywords:
Nano-drug delivery, Periodontitis, Nanotechnology, Drug formulations, Therapeutic agents, Targeted delivery, Oral healthAbstract
This comprehensive review explores the transformative potential of nano-drug delivery systems in the management of periodontitis, a prevalent oral health concern. The analysis begins with an introduction, providing a foundational understanding of the evolution of nanotechnology and its application in drug delivery. The subsequent sections delve into nanoemulsion formulations, highlighting their significance in optimizing drug delivery efficiency. The integration of various therapeutic agents within nano-drug delivery systems, including antibiotics, anti-inflammatory agents, and growth factors, demonstrates the versatility of these platforms in addressing the multifaceted nature of periodontitis. The exploration of moxifloxacin as a case study illustrates the potential impact of specific drug incorporation within nano-formulations, emphasizing the relevance of tailored approaches in combating microbial complexities. Addressing challenges and considerations becomes paramount, with a focus on biocompatibility, stability, and regulatory aspects. The review then navigates through cutting-edge formulations, innovative delivery technologies, and success stories in studies, providing insights into the evolving landscape and practical applications of nano-drug delivery in periodontitis treatment. Exploring emerging trends, potential applications, and future directions underscores the transformative potential of nano-drug delivery. The concluding sections synthesize key findings, outline implications for future research, and offer reflections on the significance of this field. In summary, this analysis highlights the dynamic and promising frontier of nano-drug delivery in reshaping periodontal care. The evolving field holds promise for personalized and efficient solutions, addressing the complexities of periodontitis with tailored precision. The comprehensive insights provided in this review serve as a foundation for continued exploration and advancement in the pursuit of more effective and targeted treatments for periodontitis, ultimately contributing to the improvement of oral health outcomes.
Downloads
References
1. Tonetti MS, Jepsen S, Jin L. Impact of the global burden of periodontal diseases on health, nutrition, and wellbeing of mankind: A call for global action. J Clin Periodontol. 2017;44(5):456-462.
2. Hajishengallis G, Lamont RJ. Beyond the red complex and into more complexity: The polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. Mol Oral Microbiol. 2012;27(6):409-419.
3. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. 2005;366(9499):1809-1820.
4. Kornman KS, Papapanou PN. Clinical application of the new classification of periodontal diseases: Ground rules, clarifications and "gray zones". J Periodontol. 2008;79(8):1347-1359.
5. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-160.
6. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev. 2005;57(15):2106-2129.
7. McClements DJ. Design of nano-laminated coatings to control bioavailability of lipophilic food components. Pure Appl Chem. 2011;83(4):1021-1037.
8. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2012;64:175-193.
9. Gajendiran M, Saraswathi R, Vijayalakshmi R. Nanoemulsion: An advanced mode of drug delivery system. 3 Biotech. 2018;8(3):120.
10. Chen H, Khemtong C, Yang X, Chang X. Gd-nanoparticles functionalized with folic acid as a bimodal imaging agent for cancer cell targeting. Mol Imaging. 2010;9(3):142-150.
11. Jhaveri AM, Torchilin VP. Multifunctional polymeric micelles for delivery of drugs and RNA. Front Pharmacol. 2014;5:77.
12. Hua S. Lipid-based nano-delivery systems for skin delivery of drugs and bioactives. Front Pharmacol. 2014;5:254.
13. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine (Lond). 2007;3(1):20-31.
14. Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: General approaches and a review of recent developments. J R Soc Interface. 2011;8(55):153-170.
15. Kim S, Nishimoto SK, Bumgardner JD, Haggard WO, Gaber MW. Nanostructured polymer coatings for local and sustained delivery of the antibiotic ciprofloxacin. Biomaterials. 2008;29(33):4739-4748.
16. Zhang L, Pornpattananangkul D, Hu CM, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem. 2010;17(6):585-594.
17. Torchilin V. Drug targeting. Eur J Pharm Sci. 2000;11.
18. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2011;63(4-5):222-235.
19. Yamaguchi H, Kojima K, Inui T, Nakashima H, Yamamoto N. Efficacy of moxifloxacin against periodontopathic bacteria in vitro and in human periodontal ligament cells. J Periodont Res. 2013;48(3):377-382.
20. Langtry HD, Campoli-Richards DM. Moxifloxacin. Drugs. 1999;58(4):617-647.
21. Miranda PV, de Araujo RF Jr, Leite AM, Sabino JP, Silva HC, Monteiro JC. "Nanotechnology in periodontal disease therapy: A systematic review." J Appl Oral Sci. 2021, Apr 5;29.
22. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev. 2005;57(15):2106-2129.
23. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2006;5(2):145-160.
24. Jain RK, Stylianopoulos T, Munn LL. Role of normalization in tumor pathophysiology: Theoretical framework, methods, and challenges. Am J Physiol Cell Physiol. 2014;307(7).
25. Mitragotri S, Lahann J. Physical approaches to biomaterial design. Nat Mater. 2009;8(1):15-23.
26. Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2016;1(12):16071.
27. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.
28. Hua S, Wu SY. The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol. 2013;4:143.
29. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2014;66:2-25.
30. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-951.
31. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med. 2019;4(3).
32. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602-2663.
33. Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release. 2011;153(3):198-205.
34. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
35. Chomoucka J, Drbohlavova J, Huska D, Adam V. Nanocarriers for anticancer drugs-new trends in nanomedicine. Curr Drug Metab. 2014;15(6):547-564.
36. Peppas NA, Khademhosseini A. Make nanobots from natural materials. Science. 2016;351(6278):460-461.
37. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813-827.
38. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: Progress, challenges, and opportunities. Nat Rev Cancer. 2017;17(1):20-37.
39. Langer R. Drug delivery and targeting. Nature. 2015;526(7573):7498.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Manisha Mishra, Rishabh Maurya, Meena Yadav
This work is licensed under a Creative Commons Attribution 4.0 International License.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
